We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Longboard Pharmaceuticals Inc | NASDAQ:LBPH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -0.14% | 35.95 | 31.00 | 39.60 | 37.21 | 35.54 | 35.90 | 607,867 | 01:00:00 |
CUSIP NO: 54300N103 | Page 2 of 5 |
1. | NAMES OF REPORTING PERSONS Pfizer Inc. (“Pfizer”) | ||||||||||||||||||||||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) | ||||||||||||||||||||||
3. | SEC USE ONLY | ||||||||||||||||||||||
4. | SOURCE OF FUNDS OO | ||||||||||||||||||||||
5. | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | ||||||||||||||||||||||
6. | CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE | ||||||||||||||||||||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 7. | SOLE VOTING POWER 0 | |||||||||||||||||||||
8. | SHARED VOTING POWER 3,978,540 shares of Common Stock, $0.0001 par value per share (“Common Stock” held by Arena Pharmaceuticals, Inc., a wholly-owned subsidiary of Pfizer. | ||||||||||||||||||||||
9. | SOLE DISPOSITIVE POWER 0 | ||||||||||||||||||||||
10. | SHARED DISPOSITIVE POWER 3,978,540 shares of Common Stock held directly by Arena Pharmaceuticals, Inc., a wholly-owned subsidiary of Pfizer. | ||||||||||||||||||||||
11. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,978,540(1) | ||||||||||||||||||||||
12. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ||||||||||||||||||||||
13. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 17.3%(2) | ||||||||||||||||||||||
14. | TYPE OF REPORTING PERSON CO | ||||||||||||||||||||||
(1) | Represents 3,978,540 shares held directly by Arena Pharmaceuticals, Inc. (“Arena” and together with Pfizer, the “Reporting Persons”). Pfizer may be deemed to have beneficial ownership over such shares since Arena is a wholly-owned subsidiary of Pfizer. | |||||||
(2) | The percentage is calculated based on 22,965,350 shares of Common Stock outstanding as of February 28, 2023, as reported in the Issuer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed on March 3, 2023. On February 8, 2023, the Issuer filed with the U.S. Securities and Exchange Commission (the “Commission”) a prospectus supplement, dated February 7, 2023 (the “Prospectus Supplement”), to its registration statement on Form S-3 (Registration No. 333-267674), filed with the Commission on September 30, 2022 and declared effective on October 11, 2022, relating to the offering of 5,000,000 shares of Common Stock, which resulted in a decrease in the percentage of the outstanding shares of Common Stock beneficially owned by the Reporting Persons. |
CUSIP NO: 54300N103 | Page 3 of 5 |
1. | NAMES OF REPORTING PERSONS Arena Pharmaceuticals, Inc. | ||||||||||||||||||||||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) | ||||||||||||||||||||||
3. | SEC USE ONLY | ||||||||||||||||||||||
4. | SOURCE OF FUNDS OO | ||||||||||||||||||||||
5. | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | ||||||||||||||||||||||
6. | CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE | ||||||||||||||||||||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 7. | SOLE VOTING POWER 0 | |||||||||||||||||||||
8. | SHARED VOTING POWER 3,978,540 shares of Common Stock | ||||||||||||||||||||||
9. | SOLE DISPOSITIVE POWER 0 | ||||||||||||||||||||||
10. | SHARED DISPOSITIVE POWER 3,978,540 shares of Common Stock | ||||||||||||||||||||||
11. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,978,540 | ||||||||||||||||||||||
12. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ||||||||||||||||||||||
13. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 17.3%(1) | ||||||||||||||||||||||
14. | TYPE OF REPORTING PERSON CO | ||||||||||||||||||||||
(1) | The percentage is calculated based on 22,965,350 shares of Common Stock outstanding as of February 28, 2023, as reported in the Issuer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed on March 3, 2023. On February 8, 2023, the Issuer filed with the Commission the Prospectus Supplement to its registration statement on Form S-3 (Registration No. 333-267674), filed with the Commission on September 30, 2022 and declared effective on October 11, 2022, relating to the offering of 5,000,000 shares of Common Stock, which resulted in a decrease in the percentage of the outstanding shares of Common Stock beneficially owned by the Reporting Persons. |
CUSIP NO: 54300N103 | Page 4 of 5 |
Item 5. | Interest in Securities of the Issuer |
Item 7. | Materials to Be Filed as Exhibits |
Exhibit 1 | Joint Filing Agreement, dated as of March 21, 2022, by and between Pfizer Inc. and Arena Pharmaceuticals, Inc. (incorporated by reference to Exhibit 1 to the Statement on Schedule 13D Statement filed by the Reporting Persons with the Commission on March 21, 2022). | ||||
Exhibit 2 | Investors’ Rights Agreement by and among Longboard Pharmaceuticals, Inc. and certain of its stockholders, dated October 27, 2020 ((incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021). |
CUSIP NO: 54300N103 | Page 5 of 5 |
1 Year Longboard Pharmaceuticals Chart |
1 Month Longboard Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions